Professionals 245 Users Online

Rare Disease Treatment Market

Global Market Study on Rare Disease Treatment: Metabolic Diseases Segment by Therapeutic Area to Register the Highest Segmental CAGR of 14.2% During 2017 – 2025

Rare Disease Treatment Market Segmented By Hematology, Genetic Diseases, Neurological Diseases, Oncology Infectious Diseases, Inflammatory Diseases, Metabolic Diseases Therapeutic Area with Originator Drugs, Generic Drugs Type with Biologics, Organic Compounds Drug Class

Instances of genetic diseases to remain rampant throughout the forecast period

The rare disease treatment market covers a detailed segmentation in which the genetic diseases segment is poised to grow at a moderate pace and stay a dominant segment by therapeutic area. Almost 80 percent diseases are of genetic origin. The genetic segment is poised to reflect a significant US$ 56 Bn market valuation by the end of 2025, as per the market forecasts gathered in this research report.

Following the genetic diseases segment, the oncology segment is expected to be the runner up with regards to market share analysis with a comparatively low growth rate than the genetic diseases segment. The metabolic diseases segment is expected to show the highest growth rate to reflect a CAGR of 14.2% during the forecast period of 2017 to 2025, followed by the neurological diseases segment at 11.3% CAGR.

Rare Disease Treatment Market

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

North America region to reflect higher market revenue share as compared to other regions

North America is projected to remain the largest regional market for rare disease treatment during the period of forecast 2017-2025 with an estimated market share of almost 40% by the end of 2025. This region is expected to retain its dominance in the coming years. As far as therapeutic area is concerned, the North America rare disease treatment market is dominated by the genetic diseases segment, and is poised to grow at a robust CAGR of 8.5% during the forecast period.

The metabolic diseases testing segment by therapeutic area also shows higher potential growth rate in the North America region during the period of forecast. The primary reason for the region to project dominance is the prevalence of a well-established healthcare system as well as several reimbursement policies to organize treatments for patients suffering from rare diseases.

The genetic diseases treatment segment in the North America regional market is expected to be a lucrative segment during the 2017-2025 forecast period with an attractive market share index of 4.2.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Several aspects contribute to the growth of the rare disease treatment market

The global rare disease treatment market is impacted by several factors that directly or indirectly affect the growth of the market. According to our research report on the rare disease treatment market, the global market is poised to reflect a market valuation of US$ 198,487 Mn in 2025 and exhibit a CAGR of 8.6% during the period of forecast.

There are various factors that are responsible for the growth of the rare disease treatment market and are analyzed in this research report along with their impact few years down the line.

The report highlights the different push factors of the global rare disease treatment market such as increasing government assistance, provision of incentives to pharmaceutical companies, increasing awareness among people and social groups, the physician to physician communication to find efficient treatment methods to treat rare diseases, increase in facilities for patients affected by rare diseases, rise in the incentives for research owing to the prevalence of non-profit organizations that promote health to treat rare diseases, other government incentives and regulations such as reduced tax on pricy medicines, higher funding on the research on rare diseases and their treatments, promising regulatory assistance along with the advantage of monopolistic market etc., which contribute to the growth of the global rare disease treatment market.

There are few other factors that pull the growth of the global market, such as the challenges in the research and development, delay in diagnosis thereby delaying the treatment, limitations with respect to expertise, characteristic lack of attractiveness from an economic standpoint, which eventually has resulted in the scarce commercial interest for private investors, lack of regulatory framework in developing economies coupled with lack of skilled healthcare personnel.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

The global rare disease treatment market research report covers all the angles by including a robust segmentation of the entire market. This ensures no aspect is left behind and a more real picture of the market can be drawn.

Attribute Details

By Therapeutic Area

  • Hematology
  • Genetic Diseases
  • Neurological Diseases
  • Oncology
  • Infectious Diseases
  • Inflammatory Diseases
  • Metabolic Diseases
  • Pulmonary Diseases
  • Kidney Diseases
  • Musculoskeletal Diseases
  • Endocrine Diseases
  • Skin Disorders

By Drug Type

  • Originator Drugs (Patented Molecules)
  • Generic Drugs

By Drug Class

  • Biologics
  • Organic Compounds

By Mode of Administration

  • Injectable
  • Oral
  • Others (includes topical preparations)

By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific (APAC)
  • Middle East and Africa (MEA)
Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

- Companies Covered in This Report -

  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Celgene Corporation
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Shire
  • Alexion
  • Novo Nordisk A/S
  • Sanofi
  • Bayer AG
  • Amgen, Inc.
  • Allergan plc.
  • Eisai Co. Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Vertex Pharmaceuticals
  • Baxter
  • BioMarin
  • Teva Pharmaceutical Industries Ltd.
  • Others

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate